Human immunodeficiency virus associated lymphoma.
OBJECTIVE
Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of systemic nonHodgkin lymphoma, Hodgkin disease, and primary central nervous lymphoma (PCNSL). The purpose of this review is to highlight recent advances in the diagnosis and management of lymphoma occurring in patients with HIV infection.


RESULTS
Lymphoma occurring in patients with HIV infection has been associated with a very poor prognosis. Recently reported studies have provided new information regarding the influence of highly active antiretroviral therapy (HAART) on the development and clinical presentation of lymphoma, the feasibility of combining HAART with standard chemotherapy, the molecular classification of lymphoma, the role of rituximab in the management of lymphoma, and the use of novel treatment strategies for the treatment of Hodgkin disease.


CONCLUSIONS
The improved prognosis for patients with HIV-associated lymphoma in the post-HAART era indicates that therapeutic interventions may be potentially curative, and represent a shift away from therapeutic nihilism and reduced-intensity treatment approaches that have been employed in the recent past.
Sparano
Joseph A
JA
Albert Einstein College of Medicine and Cancer Center, Montefiore Medical Center, Bronx, New York 10461, USA. jsparano@montefiore.org
D019380:Anti-HIV Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000175:diagnosis* / Q000628:therapy*; D033581:Stem Cell Transplantation
D019380:Anti-HIV Agents; D000970:Antineoplastic Agents